Literature DB >> 20105087

Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib.

Axel Bex, Astrid A M Van der Veldt, Christian Blank, Martijn R Meijerink, Epie Boven, John B A G Haanen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20105087     DOI: 10.3109/02841860903521111

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


× No keyword cloud information.
  14 in total

1.  [Systemic therapy of renal cell carcinoma].

Authors:  M Staehler; C Tüllmann; P Nuhn; N Haseke; C G Stief
Journal:  Urologe A       Date:  2010-12       Impact factor: 0.639

2.  Early ultrasonographic evaluation of tumor thrombus level during sunitinib therapy for renal cell carcinoma.

Authors:  Futoshi Sano; Syusei Fusayasu; Shinji Otake; Hiroyuki Yamanaka; Tomoyuki Tatenuma; Ryoko Sakata; Kazuhide Makiyama; Noboru Nakaigawa; Masahiro Yao; Yoshinobu Kubota
Journal:  J Med Ultrason (2001)       Date:  2013-05-01       Impact factor: 1.314

3.  Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.

Authors:  Jose A Karam; Catherine E Devine; Diana L Urbauer; Marisa Lozano; Tapati Maity; Kamran Ahrar; Pheroze Tamboli; Nizar M Tannir; Christopher G Wood
Journal:  Eur Urol       Date:  2014-02-07       Impact factor: 20.096

Review 4.  Is there a role for systemic targeted therapy after surgical treatment for metastases of renal cell carcinoma?

Authors:  Adrian Husillos Alonso; Manuel Carbonero García; Carmen González Enguita
Journal:  World J Nephrol       Date:  2015-05-06

Review 5.  Game of thrones: immunotherapy versus molecular targeted therapy in renal cell cancer scenarios.

Authors:  Bulent Cetin; Alim Kosar
Journal:  Int Urol Nephrol       Date:  2019-08-29       Impact factor: 2.370

Review 6.  Targeted therapies in renal cell cancer: recent developments in imaging.

Authors:  Astrid A M van der Veldt; Martijn R Meijerink; Alfons J M van den Eertwegh; Epie Boven
Journal:  Target Oncol       Date:  2010-07-14       Impact factor: 4.493

7.  Neoadjuvant targeted therapy in a primary metastasized renal cell cancer patient leads to down-staging of inferior vena cava thrombus (IVC) enabling a cardiopulmonary bypass-free tumor nephrectomy: a case report.

Authors:  Inga Peters; Michael Winkler; Björn Jüttner; Omke E Teebken; T R Herrmann; Christoph von Klot; Mario Kramer; Angela Reichelt; Mahmoud Abbas; Markus A Kuczyk; Axel S Merseburger
Journal:  World J Urol       Date:  2012-09-30       Impact factor: 4.226

8.  Expression and role of VEGFA and miR-381 in portal vein tumor thrombi in patients with hepatocellular carcinoma.

Authors:  Jing Wang; Shuzhi Wu; Tianren Huang
Journal:  Exp Ther Med       Date:  2018-05-03       Impact factor: 2.447

Review 9.  Do targeted agents offer clinical benefit as presurgical therapy?

Authors:  Axel Bex; John Haanen
Journal:  World J Urol       Date:  2013-02-26       Impact factor: 4.226

Review 10.  The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma.

Authors:  Leonardo D Borregales; Mehrad Adibi; Arun Z Thomas; Christopher G Wood; Jose A Karam
Journal:  Ther Adv Urol       Date:  2015-11-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.